Advertisement

Drugs

, Volume 79, Issue 16, pp 1797–1803 | Cite as

Pretomanid: First Approval

  • Susan J. KeamEmail author
AdisInsight Report
  • 181 Downloads

Abstract

Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for tuberculosis (TB). TB Alliance has licensed Mylan to manufacture and commercialize pretomanid for use as part of the BPaMZ and BPaL regimens. The license is non-exclusive in low- and middle-income countries and exclusive in high-income markets. Pretomanid, as part of the BPaL regimen, was recently approved in the USA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) pathway for the treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or non-responsive multidrug-resistant (MDR) TB. Pretomanid is also under regulatory review in the EU. This article summarizes the milestones in the development of pretomanid leading to this first regulatory approval.

Notes

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan Keam is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–6.CrossRefGoogle Scholar
  2. 2.
    TB Alliance. The pandemic: a global threat. 2019. https://www.tballiance.org/why-new-tb-drugs/global-pandemic. Accessed 28 Aug 2019.
  3. 3.
    Gothi D, Joshi JM. Resistant TB: newer drugs and community approach. Recent Pat Anti Infect Drug Disc. 2011;6(1):27–37.CrossRefGoogle Scholar
  4. 4.
    Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):38–41.CrossRefGoogle Scholar
  5. 5.
    TB Alliance. Novartis sets deal to seek new drugs for fighting TB. 2004. https://www.tballiance.org/news/novartis-sets-deal-seek-new-drugs-fighting-tb. Accessed 27 Aug 2019.
  6. 6.
    The Global Alliance for TB Drug Development (TB Alliance). Pretomanid tablets: US prescribing information. 2019. https://www.fda.gov/. Accessed 27 Aug 2019.
  7. 7.
    US Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs [media release]. Aug 14 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs.
  8. 8.
    European Medicines Agency. Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use: April 2019. 2019. https://www.ema.europa.eu/en/medicines/medicines-under-evaluation. Accessed 27 Aug 2019.
  9. 9.
    Chiron Corporation. Chiron compound enters clinical trials through the Global Alliance for TB Drug Development; phase I studies to begin for first tuberculosis drug developed by a public-private partnership [media release]. Jun 14 2005. http://www.chiron.com.
  10. 10.
    Chiron Corporation. Chiron announces merger agreement with Novartis [media release]. Oct 31 2005. https://www.sec.gov/Archives/edgar/data/706539/000110465905051182/a05-19282_1ex99d1.htm.
  11. 11.
    Mylan. TB Alliance and Mylan announce global collaboration to commercialize investigational drug pretomanid as part of two regimens to treat tuberculosis (TB) [media release]. Apr 18 2019. http://www.mylan.com.
  12. 12.
    Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol. 2009;2(3):215–8.CrossRefGoogle Scholar
  13. 13.
    Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science. 2008;322(5906):1392–5.CrossRefGoogle Scholar
  14. 14.
    Lenaerts AJ, Gruppo V, Marietta KS, et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob Agents Chemother. 2005;49(6):2294–301.CrossRefGoogle Scholar
  15. 15.
    Li SY, Tasneen R, Tyagi S, et al. Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2017.  https://doi.org/10.1128/AAC.00913-17.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(4):1522–4.CrossRefGoogle Scholar
  17. 17.
    Somasundaram S, Anand RS, Venkatesan P, et al. Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC Microbiol. 2013;13:218.CrossRefGoogle Scholar
  18. 18.
    Tyagi S, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2005;49(6):2289–93.CrossRefGoogle Scholar
  19. 19.
    Wen S, Jing W, Zhang T, et al. Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. Eur J Clin Microbiol Infect Dis. 2019;38(7):1293–6.CrossRefGoogle Scholar
  20. 20.
    Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother. 2008;52(10):3664–8.CrossRefGoogle Scholar
  21. 21.
    Tasneen R, Betoudji F, Tyagi S, et al. Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2016;60(1):270–7.CrossRefGoogle Scholar
  22. 22.
    Xu J, Li SY, Almeida DV, et al. Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis. Antimicrob Agents Chemother. 2019.  https://doi.org/10.1128/AAC.00021-19.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Feuerriegel S, Koser CU, Bau D, et al. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother. 2011;55(12):5718–22.CrossRefGoogle Scholar
  24. 24.
    Haver HL, Chua A, Ghode P, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59(9):5316–23.CrossRefGoogle Scholar
  25. 25.
    Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010;54(8):3402–7.CrossRefGoogle Scholar
  26. 26.
    Diacon AH, Dawson R, du Bois J, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother. 2012;56(6):3027–31.CrossRefGoogle Scholar
  27. 27.
    Dawson R, Diacon AH, Everitt D, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015;385(9979):1738–47.CrossRefGoogle Scholar
  28. 28.
    Dooley KE, Luetkemeyer AF, Park JG, et al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir–ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014;58(9):5245–52.CrossRefGoogle Scholar
  29. 29.
    Conradie A, Everitt D, Mendel C, et al. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid [abstract no. OA03-213-25 and presentation]. Int J Tuberc Lung Dis. 2018;22(Suppl. 2):S69.Google Scholar
  30. 30.
    Dawson R, Harris K, Conradie A, et al. Efficacy of bedaquiline, pretomanid, moxifloxacin & PZA (BPaMZ) against DS- & MDR-TB [abstract no. 724LB]. Top Antivir Med. 2017;25(Suppl. 1):310s.Google Scholar
  31. 31.
    Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet. 2012;380(9846):986–93.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations